Aster Insights Emerges as the Rebranded Version of M2GEN

M2Gen, the leading oncology bioinformatics company, is transforming the medical product discovery process with its revolutionary lifetime-consented clinicogenomic data. To mark this new era of accelerated innovation, the company is proud to announce its rebranding and new name: Aster Insights™.

For the last 15 years, the company has been at the nexus of patients, researchers, and the life sciences industry, pioneering the way in patient engagement, oncology research and discovery. Leveraging its unique clinical and molecular dataset, the company has enabled groundbreaking insights that have accelerated target identification and drug discovery. With a new rebrand, the company celebrates its trailblazing journey and ongoing growth in the oncology and genomics space.

At Aster Insights, we are on a mission to chart a pioneering course of action in the pursuit of new knowledge, with the aim of unlocking the mysteries of precision oncology and finding a cure. Our offerings include advanced data products, consultative services, and software platforms — all of which draw inspiration from the stars, with the Greek word for star, ‘Aster’, being the namesake of our company.

By taking this bold and visionary approach, we are dedicated to helping cancer researchers and industry partners navigate the complexities of the field and make strides towards making a real difference.

Aster Insights is on a mission to revolutionize oncology discovery research by utilizing the power of whole exome sequencing (DNA), whole transcriptome sequencing (RNA) and germline DNA sequencing of patient samples.

To further its mission, Aster Insights created the Oncology Research Information Exchange Network® (ORIEN), a federated consortium of leading U.S. cancer centers, to facilitate collaboration between research and clinical trial entities.

Most notably, Aster Insights’ patient-oriented solution is based on lifetime patient consent by way of the Total Cancer Care® (TCC) protocol, making it the first-ever longitudinal database of cancer patients.

Aster Insights is seizing a unique opportunity to revolutionize the way cancer is studied and treated. With a new brand, a strategic vision, and a suite of enhanced products, Aster Insights is set to become the go-to source for the richest real-world dataset with the deepest molecular data insights available in oncology. With the precision medicine and drug discovery markets rapidly expanding, Aster Insights is poised to make a major impact on the field.

About Aster Insights

At Aster Insights, we are revolutionizing cancer care with the power of personalized medicine. Our innovative dataset accelerates the discovery, development, and delivery of therapies tailored to each individual patient.

We are the only bioinformatics company with lifetime, patient-consented longitudinal clinical data and whole exome (WES) and whole transcriptome (WTS) sequencing, both for tumor and germline data. Our Oncology Research Information Exchange Network® (ORIEN) is an alliance of NCI-Designated cancer centers that collect de-identified and lifetime-consented clinical and genomic patient data for research. With Aster Insights, you can trust that you are receiving the best care for your individual needs.

Leave a Comment